Results 291 to 300 of about 2,298,895 (410)

Mutual Exclusion Analysis Shows that DUSP9 Negatively Regulates PD‐L1 Expression and Acts as a Target to Enhance Anti‐PD‐1 Efficacy

open access: yesAdvanced Science, EarlyView.
A mutually exclusive screening system is established to identify negative regulators of highly plastic genes. Dual specificity phosphatase (DUSP9) is a novel negative regulatory molecule of PD‐L1 by dephosphorylating STAT3, and acts as a target molecule in combination with PD‐1 antibody for tumor immunotherapy and a new clinical biomarker for ...
Yuzhe Hu   +9 more
wiley   +1 more source

Five Years Follow-up of Imlifidase Desensitized Kidney Transplant Recipients. [PDF]

open access: yesTranspl Int
Lorant T   +11 more
europepmc   +1 more source

Understanding Medication Nonadherence after Kidney Transplant.

open access: yesJournal of the American Society of Nephrology, 2017
T. Nevins, P. Nickerson, M. Dew
semanticscholar   +1 more source

Irradiated Tumor Cell‐Derived Microparticles Activate Systemic Anti‐Tumor Immunity via the STING/NLRP3/GSDMD Axis in Neutrophils

open access: yesAdvanced Science, EarlyView.
Radiotherapy induces tumor cells to release microparticles (RT‐MPs) into the circulation. The mitochondrial DNA carried by these RT‐MPs activates the STING/NLRP3/GSDMD axis in splenic neutrophils, triggering IL‐1β secretion. This, in turn, enhances dendritic cell function and facilitates the formation of cytotoxic T lymphocytes, thereby promoting ...
Yan Hu   +18 more
wiley   +1 more source

WCN24-1043 FRAILTY PHENOTYPE AMONG KIDNEY TRANSPLANT CANDIDATES: PREVALENCE AND ASSOCIATED FACTORS

open access: yesKidney International Reports
Raoni de Oliveira Domingues da Silva   +10 more
doaj   +1 more source

IMPROVEMENT OF RESULTS OF KIDNEY TRANSPLANTATION

open access: diamond, 2015
A. G. Stolyar   +3 more
openalex   +2 more sources

KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary.

open access: yesKidney International, 2010
B. Kasiske   +20 more
semanticscholar   +1 more source

Targeting DESI2 as a Novel Therapeutic Strategy for JAK2‐Mutant Leukemias

open access: yesAdvanced Science, EarlyView.
Mass spectrometry‐based proteomics identify DESI2 as a novel component of the JAK2‐V617F complex, which associates with and stabilizes mutant JAK2 through deSUMOylation and deubiquitination, therefore promoting JAK2 mutant cell growth and MPN disease onset in vivo.
Husheng Mei   +32 more
wiley   +1 more source

Home - About - Disclaimer - Privacy